Pipeline Insight: Osteoporosis

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2005-10-25

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Osteoporosis is a degenerative skeletal disorder characterized by an increase in bone fragility and fracture risk due to a loss of bone mass and microarchitectural deterioration. The most serious clinical expression of osteoporosis is fracture. Despite the availability of a number of drugs capable of reducing fracture risk by over 50%, the use of drugs to prevent bone loss remains inadequate.


Scope

  • Epidemiology of osteoporosis in the seven major markets by disease severity, identification of niche populations and unmet needs
  • Detailed profiles of drugs in late-stage development examining clinical data, patient potential, marketing factors, satisfaction of unmet needs
  • Primary research with key osteoporosis opinion leaders providing insight on future market entrants and innovative R&D projects in the disease area
  • Evaluation of key company activity in this market looking at lifecycle management among current leaders and R&D commitments of future players


    • Report Highlights
    Bisphosphonates will remain the gold-standard approach to osteoporosis treatment due to familiarity among prescribers, genericization of leading brands and innovations in dosing among novel products. Other antiresorptive agents will significant potential be limited by high costs, safety concerns and inadequate commercial development plans.

    The osteoporosis pipeline is top-heavy, with 50% of drug candidates in Phase III or higher. Investment is evident across therapeutic classes, particularly in improving peptide delivery methods, although anabolic therapies are dominated by early-Phase PTH drugs and comprise only one-fifth of total pipeline candidates.

    Datamonitor has identified the five most promising compounds in development for osteoporosis which together will account for nearly 80% of revenues from pipeline products in 2015. The overriding trend in these top brands is long-interval, intermittent dosing that aims to address the need for improved patient compliance.


    Reasons to Purchase

  • Appreciate key trends in the approach to osteoporosis treatment and prevention and identify opportunities in areas of unmet need
  • Quantify the commercial potential of therapeutic drug classes and key products and understand the reasons for success
  • Understand the impact of genericization in the market and the future challenges faced by novel therapies

    • Table of Contents

    Other users found this report page using the following search terms: osteoporosis bone menopause osteoporosis denusomab aclasta 2008 license preos forteo hiv fosavance fortical

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.